
Simion I Chiosea

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5156096/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Alternate diagnostic test interpretation in a retrospective convenience cohort and clinical application of <scp>MPTX</scp> . Diagnostic Cytopathology, 2021, 49, 347-348.	1.0	3
2	Evaluation of NR4A3 immunohistochemistry (IHC) and fluorescence in situ hybridization and comparison with DOG1 IHC for FNA diagnosis of acinic cell carcinoma. Cancer Cytopathology, 2021, 129, 104-113.	2.4	34
3	Primary and Secondary/ Metastatic Salivary Duct Carcinoma Presenting within the Sinonasal Tract. Head and Neck Pathology, 2021, 15, 769-779.	2.6	6
4	Clinicopathologic Characteristics of Thyroid Nodules Positive for the <i>THADA-IGF2BP3</i> Fusion on Preoperative Molecular Analysis. Thyroid, 2021, 31, 1212-1218.	4.5	16
5	Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fineâ€needle aspirates diagnosed as follicular neoplasm of Hürthle cell (oncocytic) type. Cancer Cytopathology, 2021, 129, 788-797.	2.4	9
6	RB1, p16, and Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma. Head and Neck Pathology, 2021, 15, 1109-1118.	2.6	8
7	SSTR2 Expression in Olfactory Neuroblastoma: Clinical and Therapeutic Implications. Head and Neck Pathology, 2021, 15, 1185-1191.	2.6	17
8	Molecular alterations in Hürthle cell nodules and preoperative cancer risk. Endocrine-Related Cancer, 2021, 28, 301-309.	3.1	23
9	Mucoacinar Carcinoma. American Journal of Surgical Pathology, 2021, 45, 1028-1037.	3.7	20
10	Hamartoma of the Oral Cavity with Ectopic Meningothelial Elements in Infants: A Rare Entity with Report of Two Cases. Head and Neck Pathology, 2020, 14, 268-271.	2.6	7
11	The role of adjuvant (chemo-)radiotherapy in oral cancers in the contemporary era. Oral Oncology, 2020, 102, 104563.	1.5	14
12	Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers. Scientific Reports, 2020, 10, 8031.	3.3	12
13	Intraoperative Margin Assessment in Head and Neck Cancer: A Case of Misuse and Abuse?. Head and Neck Pathology, 2020, 14, 291-302.	2.6	24
14	Transition to a virtual multidisciplinary tumor board during the COVID â€19 pandemic: University of Pittsburgh experience. Head and Neck, 2020, 42, 1310-1316.	2.0	64
15	Malignant Neoplasms of the Salivary Glands. , 2019, , 284-362.e5.		1
16	On challenges of disproving inferiority of tumor bed margins. Oral Diseases, 2019, 25, 2040-2041.	3.0	1
17	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i> -altered head and neck cancer. Journal of Experimental Medicine, 2019, 216, 419-427.	8.5	46
18	Early squamous cell carcinoma of the oral tongue with histologically benign lymph nodes: A model predicting local control and vetting of the eighth edition of the American Joint Committee on Cancer pathologic T stage. Cancer, 2019, 125, 3198-3207.	4.1	24

#	Article	IF	CITATIONS
19	Genomic analysis of recurrences and highâ€grade forms of polymorphous adenocarcinoma. Histopathology, 2019, 75, 193-201.	2.9	10
20	The HTN3-MSANTD3 Fusion Gene Defines a Subset of Acinic Cell Carcinoma of the Salivary Gland. American Journal of Surgical Pathology, 2019, 43, 489-496.	3.7	52
21	Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology. JAMA Oncology, 2019, 5, 204.	7.1	317
22	GLIS Rearrangement is a Genomic Hallmark of Hyalinizing Trabecular Tumor of the Thyroid Gland. Thyroid, 2019, 29, 161-173.	4.5	69
23	Measuring Depth of Invasion in Early Squamous Cell Carcinoma of the Oral Tongue: Positive Deep Margin, Extratumoral Perineural Invasion, and Other Challenges. Head and Neck Pathology, 2019, 13, 154-161.	2.6	49
24	Characterization of thyroid cancer driven by known and novel ALK fusions. Endocrine-Related Cancer, 2019, 26, 803-814.	3.1	38
25	Standardized Margin Assessment Is Needed Before Implementing Negative Margin as a Quality Measure. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 541.	2.2	2
26	Epithelial-Myoepithelial Carcinoma. American Journal of Surgical Pathology, 2018, 42, 18-27.	3.7	71
27	Clear Cell Carcinoma of Salivary Glands Is Frequently p16 Positive. American Journal of Surgical Pathology, 2018, 42, 367-371.	3.7	23
28	Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland. American Journal of Surgical Pathology, 2018, 42, 442-452.	3.7	91
29	Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. BMC Cancer, 2018, 18, 1107.	2.6	12
30	Patients with revised surgical resection margins are best studied as a distinct group. Cancer, 2018, 124, 4262-4263.	4.1	1
31	Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nature Communications, 2017, 8, 14121.	12.8	227
32	<i>THADA</i> fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 2307-2312.	7.1	58
33	Frequent <i>IDH2</i> R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. Journal of Pathology, 2017, 242, 400-408.	4.5	83
34	Solid Lymph Nodes as an Imaging Biomarker for Risk Stratification in Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma. American Journal of Neuroradiology, 2017, 38, 1405-1410.	2.4	18
35	<scp>HMGA</scp> 2 is a specific immunohistochemical marker for pleomorphic adenoma and carcinoma exâ€pleomorphic adenoma. Histopathology, 2017, 71, 511-521.	2.9	56
36	Reappraising hyalinizing clear cell carcinoma: A populationâ€based study with molecular confirmation. Head and Neck, 2017, 39, 503-511.	2.0	29

#	Article	IF	CITATIONS
37	Phosphaturic Mesenchymal Tumors. American Journal of Surgical Pathology, 2017, 41, 1371-1380.	3.7	77
38	SMARCB1 (INI-1)-deficient Sinonasal Carcinoma. American Journal of Surgical Pathology, 2017, 41, 458-471.	3.7	198
39	Clinical and Morphologic Features of ETV6-NTRK3 Translocated Papillary Thyroid Carcinoma in an Adult Population Without Radiation Exposure. American Journal of Surgical Pathology, 2017, 41, 446-457.	3.7	61
40	Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry. Head and Neck Pathology, 2017, 11, 288-294.	2.6	53
41	Intraoperative Margin Assessment in Early Oral Squamous Cell Carcinoma. Surgical Pathology Clinics, 2017, 10, 1-14.	1.7	30
42	Improving margin revision: Characterization of tumor bed margins in early oral tongue cancer. Oral Oncology, 2017, 75, 184-188.	1.5	21
43	Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein–Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines. Head and Neck Pathology, 2017, 11, 203-211.	2.6	23
44	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. JCI Insight, 2017, 2, e90449.	5.0	45
45	Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Annals of Oncology, 2016, 27, 1594-1600.	1.2	48
46	Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, <i>PLAG1</i> or <i>HMGA2</i> rearrangements, and common genetic alterations. Cancer, 2016, 122, 3136-3144.	4.1	73
47	Does a specimenâ€based margin analysis of early tongue cancer better predict local control?. Laryngoscope, 2016, 126, 2426-2427.	2.0	12
48	MAML2 Status in Mucoepidermoid Carcinoma Can No Longer Be Considered a Prognostic Marker. American Journal of Surgical Pathology, 2016, 40, 1151-1153.	3.7	35
49	Phosphaturic Mesenchymal Tumor Involving the Head and Neck: A Report of Five Cases with FGFR1 Fluorescence In Situ Hybridization Analysis. Head and Neck Pathology, 2016, 10, 279-285.	2.6	24
50	Prevalence and phenotypic correlations of EIF1AX mutations in thyroid nodules. Endocrine-Related Cancer, 2016, 23, 295-301.	3.1	81
51	Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the <i>BRAF^{K601E}</i> Mutation. Thyroid, 2016, 26, 242-247.	4.5	83
52	Clinicopathologic and Immunophenotypic Characterization of 25 Cases of Acinic Cell Carcinoma with High-Grade Transformation. Head and Neck Pathology, 2016, 10, 152-160.	2.6	58
53	The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget, 2016, 7, 27185-27198.	1.8	37
54	TMEM16A/ANO1 is differentially expressed in HPV-negative versus HPV-positive head and neck squamous cell carcinoma through promoter methylation. Scientific Reports, 2015, 5, 16657.	3.3	37

#	Article	IF	CITATIONS
55	Molecular Characterization of Apocrine Salivary Duct Carcinoma. American Journal of Surgical Pathology, 2015, 39, 744-752.	3.7	102
56	The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. Journal of Cellular Physiology, 2015, 230, 2683-2694.	4.1	58
57	Salivary Duct Carcinoma. American Journal of Surgical Pathology, 2015, 39, 705-713.	3.7	126
58	Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology. Thyroid, 2015, 25, 1217-1223.	4.5	344
59	Canalicular Adenoma: A Clinicopathologic and Immunohistochemical Analysis of 67 Cases with a Review of the Literature. Head and Neck Pathology, 2015, 9, 181-195.	2.6	50
60	Early Oral Tongue Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2015, 141, 1104.	2.2	102
61	JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth. Neoplasia, 2015, 17, 256-264.	5.3	59
62	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncology, 2015, 1, 238.	7.1	44
63	Primary RET-mutated lung neuroendocrine carcinoma in MEN2B: response to RET-targeted therapy. Endocrine-Related Cancer, 2015, 22, L19-L22.	3.1	1
64	Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. Journal of Clinical Investigation, 2015, 126, 169-180.	8.2	156
65	Human papillomavirus and Epstein–Barr virus in nasopharyngeal carcinoma in a lowâ€incidence population. Head and Neck, 2014, 36, 511-516.	2.0	71
66	Metastasis of Breast Carcinoma to the Maxillary Sinus. Breast Journal, 2014, 20, 318-319.	1.0	2
67	Novel <i>PRKD</i> gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes and Cancer, 2014, 53, 845-856.	2.8	128
68	HRAS Mutations in Epithelial–Myoepithelial Carcinoma. Head and Neck Pathology, 2014, 8, 146-150.	2.6	72
69	Human Papillomavirus-Associated Adenocarcinoma of the Base of Tongue: Potentially Actionable Genetic Changes. Head and Neck Pathology, 2014, 8, 151-156.	2.6	10
70	Carcinoma Ex-Schneiderian Papilloma (Malignant Transformation): A Clinicopathologic and Immunophenotypic Study of 20 Cases Combined with a Comprehensive Review of the Literature. Head and Neck Pathology, 2014, 8, 269-286.	2.6	94
71	Margin assessment in oral squamous cell carcinoma. Cancer, 2014, 120, 452-453.	4.1	6
72	Salivary duct carcinoma and the concept of early carcinoma ex pleomorphic adenoma. Histopathology, 2014, 65, 854-860.	2.9	43

5

#	Article	IF	CITATIONS
73	KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. Modern Pathology, 2014, 27, 262-270.	5.5	32
74	Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 nextâ€generation sequencing assay. Cancer, 2014, 120, 3627-3634.	4.1	445
75	Thyroid nodules with <i>KRAS</i> mutations are different from nodules with <i>NRAS</i> and <i>HRAS</i> mutations with regard to cytopathologic and histopathologic outcome characteristics. Cancer Cytopathology, 2014, 122, 873-882.	2.4	63
76	Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer. Clinical Cancer Research, 2014, 20, 3289-3298.	7.0	48
77	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics, 2014, 46, 1166-1169.	21.4	188
78	Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chemical Biology, 2013, 8, 345-352.	3.4	41
79	Mammary Analogue Secretory Carcinoma Mimicking Salivary Adenoma. Head and Neck Pathology, 2013, 7, 316-319.	2.6	32
80	Early squamous cell carcinoma of the oral tongue: Comparing margins obtained from the glossectomy specimen to margins from the tumor bed. Oral Oncology, 2013, 49, 1077-1082.	1.5	64
81	PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer, 2013, 13, 602.	2.6	56
82	Pathology Quiz Case 3. JAMA Otolaryngology - Head and Neck Surgery, 2013, 139, 533.	2.2	1
83	Extracapsular spread in head and neck carcinoma: Impact of site and human papillomavirus status. Cancer, 2013, 119, 3302-3308.	4.1	159
84	The cytological features of mammary analogue secretory carcinoma. Cancer Cytopathology, 2013, 121, 234-241.	2.4	105
85	Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers. Cancer Discovery, 2013, 3, 761-769.	9.4	505
86	The prognostic and predictive value of <i>KRAS</i> oncogene substitutions in lung adenocarcinoma. Cancer, 2013, 119, 2268-2274.	4.1	49
87	The mutational landscape of adenoid cystic carcinoma. Nature Genetics, 2013, 45, 791-798.	21.4	394
88	KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas. Modern Pathology, 2013, 26, 1346-1354.	5.5	65
89	PIK3CA Mutations and PTEN Loss in Salivary Duct Carcinomas. American Journal of Surgical Pathology, 2013, 37, 1201-1207.	3.7	66
90	Colorectal carcinomas, KRAS p.G13D mutant allele–specific imbalance, and anti–epidermal growth factor receptor therapy. Cancer, 2013, 119, 4366-4366.	4.1	3

#	Article	IF	CITATIONS
91	First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy. Cancer Discovery, 2012, 2, 694-705.	9.4	260
92	Thyroid Paragangliomas Are Locally Aggressive. Thyroid, 2012, 22, 88-93.	4.5	33
93	Lyn Kinase Mediates Cell Motility and Tumor Growth in EGFRvIII-Expressing Head and Neck Cancer. Clinical Cancer Research, 2012, 18, 2850-2860.	7.0	30
94	DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Modern Pathology, 2012, 25, 919-929.	5.5	203
95	The Profile of Acinic Cell Carcinoma After Recognition of Mammary Analog Secretory Carcinoma. American Journal of Surgical Pathology, 2012, 36, 343-350.	3.7	183
96	First needle marrow biopsy to diagnose a systemic illness. Blood, 2012, 120, 4910-4910.	1.4	0
97	Incidence of human papillomavirus in oropharyngeal squamous cell carcinomas: now and 50 years ago. Human Pathology, 2012, 43, 17-22.	2.0	36
98	Squamous cell carcinoma metastatic to neck from an unknown primary: The potential impact of modern pathologic evaluation on perceived incidence of human papillomavirus–positive oropharyngeal carcinoma prior to 1970. Laryngoscope, 2012, 122, 793-796.	2.0	10
99	Prospective testing of mucoepidermoid carcinoma for the <i>MAML2</i> translocation: Clinical Implications. Laryngoscope, 2012, 122, 1690-1694.	2.0	51
100	Mutant alleleâ€specific imbalance modulates prognostic impact of <i>KRAS</i> mutations in colorectal adenocarcinoma and is associated with worse overall survival. International Journal of Cancer, 2012, 131, 1810-1817.	5.1	52
101	Re-Evaluating Historic Cohort of Salivary Acinic Cell Carcinoma with New Diagnostic Tools. Head and Neck Pathology, 2012, 6, 166-170.	2.6	56
102	Tribute: E. Leon Barnes, M.D. Head and Neck Pathology, 2012, 6, 54-57.	2.6	2
103	Clinicopathological characterization of mammary analogue secretory carcinoma of salivary glands. Histopathology, 2012, 61, 387-394.	2.9	222
104	Higher Dosage of the Epidermal Growth Factor Receptor Mutant Allele in Lung Adenocarcinoma Correlates with Younger Age, Stage IV at Presentation, and Poorer Survival. Journal of Thoracic Oncology, 2011, 6, 1407-1412.	1.1	12
105	Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomarkers, 2011, 9, 325-339.	1.7	34
106	Mucoepidermoid carcinoma: a five-decade journey. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 133-140.	2.8	68
107	Mammary analogue secretory carcinoma: a new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 117-118.	2.8	84
108	Oral Squamous Cell Carcinoma with Mandibular Bone Invasion: Intraoperative Evaluation of Bone Margins by Routine Frozen Section. Head and Neck Pathology, 2011, 5, 216-220.	2.6	36

#	Article	IF	CITATIONS
109	Management of the "Violated Neck―in the era of chemoradiation. Laryngoscope, 2011, 121, 2349-2358.	2.0	8
110	KRAS mutant allele-specific imbalance in lung adenocarcinoma. Modern Pathology, 2011, 24, 1571-1577.	5.5	53
111	Pathology Archive. American Journal of Clinical Pathology, 2011, 135, 753-759.	0.7	20
112	Large Cell Neuroendocrine Carcinoma of the Larynx: Definition of an Entity. Head and Neck Pathology, 2010, 4, 198-207.	2.6	68
113	Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene, 2010, 29, 5135-5145.	5.9	94
114	Solid Cell Nests, Papillary Thyroid Microcarcinoma, and HBME1. American Journal of Clinical Pathology, 2010, 134, 169-170.	0.7	10
115	Ameloblastoma and Dentigerous Cyst Associated with Impacted Mandibular Third Molar Tooth. Radiographics, 2010, 30, 1415-1420.	3.3	32
116	EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. Human Pathology, 2010, 41, 1053-1060.	2.0	24
117	MicroRNAs in Endocrine Diseases. Molecular Pathology Library, 2010, , 21-24.	0.1	0
118	Salivary type tumors seen in consultation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 457-466.	2.8	19
119	MicroRNA Expression Profiles in Thyroid Tumors. Endocrine Pathology, 2009, 20, 85-91.	9.0	110
120	A Novel Complex BRAF Mutation Detected in a Solid Variant of Papillary Thyroid Carcinoma. Endocrine Pathology, 2009, 20, 122-126.	9.0	74
121	Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of 78 cases with immunohistochemical analysis of dicer expression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 452, 629-635.	2.8	47
122	Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma. Cancer, 2008, 113, 2082-2089.	4.1	128
123	Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Modern Pathology, 2008, 21, 742-747.	5.5	188
124	Selective expression of gastric mucin MUC6 in colonic sessile serrated adenoma but not in hyperplastic polyp aids in morphological diagnosis of serrated polyps. Modern Pathology, 2008, 21, 660-669.	5.5	67
125	Overexpression of Dicer in Precursor Lesions of Lung Adenocarcinoma. Cancer Research, 2007, 67, 2345-2350.	0.9	230
126	Up-Regulation of Dicer, a Component of the MicroRNA Machinery, in Prostate Adenocarcinoma. American Journal of Pathology, 2006, 169, 1812-1820.	3.8	327

#	Article	IF	CITATIONS
127	In vitro FRAP reveals the ATP-dependent nuclear mobilization of the exon junction complex protein SRm160. Journal of Cell Biology, 2004, 164, 843-850.	5.2	31
128	Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme. Journal of Cell Science, 2004, 117, 5847-5854.	2.0	37
129	The spatial targeting and nuclear matrix binding domains of SRm160. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3269-3274.	7.1	58